602 related articles for article (PubMed ID: 23298365)
1. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
[TBL] [Abstract][Full Text] [Related]
2. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
Boiron L; Joura E; Largeron N; Prager B; Uhart M
BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
[TBL] [Abstract][Full Text] [Related]
3. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
4. Health and economic implications of HPV vaccination in the United States.
Kim JJ; Goldie SJ
N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
[TBL] [Abstract][Full Text] [Related]
5. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
Kim JJ
Lancet Infect Dis; 2010 Dec; 10(12):845-52. PubMed ID: 21051295
[TBL] [Abstract][Full Text] [Related]
6. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis.
Bogaards JA; Wallinga J; Brakenhoff RH; Meijer CJ; Berkhof J
BMJ; 2015 May; 350():h2016. PubMed ID: 25985328
[TBL] [Abstract][Full Text] [Related]
7. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
8. [Anticipated efficacy of HPV vaccination in prophylaxis against nongenital cancers].
Sehnal B; Vojáčková N; Driák D; Kmoníčková E; Vaňousová D; Maxová K; Neumannová H; Sláma J
Klin Onkol; 2014; 27(4):239-46. PubMed ID: 25115712
[TBL] [Abstract][Full Text] [Related]
9. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
Burger EA; Sy S; Nygård M; Kristiansen IS; Kim JJ
PLoS One; 2014; 9(3):e89974. PubMed ID: 24651645
[TBL] [Abstract][Full Text] [Related]
10. The HPV infection in males: an update.
Giraldi G; De Luca d'Alessandro E
Ann Ig; 2012; 24(6):497-506. PubMed ID: 23234187
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
Borracci RA; Segal SV; Méndez JH
Medicina (B Aires); 2018; 78(5):315-328. PubMed ID: 30285924
[TBL] [Abstract][Full Text] [Related]
13. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
[TBL] [Abstract][Full Text] [Related]
14. Estimating the long-term effects of HPV vaccination in Germany.
Horn J; Damm O; Kretzschmar ME; Deleré Y; Wichmann O; Kaufmann AM; Garbe E; Krämer A; Greiner W; Mikolajczyk RT
Vaccine; 2013 May; 31(19):2372-80. PubMed ID: 23518405
[TBL] [Abstract][Full Text] [Related]
15. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
Luxembourg A; Moeller E
Expert Rev Vaccines; 2017 Nov; 16(11):1119-1139. PubMed ID: 28956458
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus-related disease in men: not just a women's issue.
Palefsky JM
J Adolesc Health; 2010 Apr; 46(4 Suppl):S12-9. PubMed ID: 20307839
[TBL] [Abstract][Full Text] [Related]
17. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
19. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
20. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity.
Brisson M; van de Velde N; Franco EL; Drolet M; Boily MC
J Infect Dis; 2011 Aug; 204(3):372-6. PubMed ID: 21742835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]